Pain Seminar on ACD440 – Opportunities in erythromelalgia – Märta Segerdahl, CMO скачать в хорошем качестве

Pain Seminar on ACD440 – Opportunities in erythromelalgia – Märta Segerdahl, CMO

From our live event on August 27. Märta Segerdahl, CMO gives an update on AlzeCure's clinical phase II candidate, ACD440, and the recently received Orphan Designation from the FDA on the indication Pain in Erythromelalgia. Disclaimer Any content posted on this YouTube channel is made available for informational purposes only. It is not intended to and should not be relied upon or construed as financial advice regarding Alzecure Pharma AB (the “Company”) or any specific product, issue or factual circumstance. We, the Company, do not guarantee the accuracy or completeness of the information contained herein. Furthermore, the information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. Although the Company attempts to provide accurate and up-to-date information, no guarantee is made to that effect. You are solely allowed to access any content posted on this channel as it is presented by us, the Company. Any further use of such content (including but not limited to copying, reproducing, making available, incorporating the content into other works etc.) is subject to our prior written authorization. We, the Company, are not responsible for any third-party comments or other content that is posted, linked to or otherwise made available in relation to this content.